pharmaceuticals
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); 
ASP, generally
Medicare Part D, including removal of safe harbor protection for drug rebates
Medicare Part B, including proposals to create an international pricing index, establish a competitive acquisition program Legislation to prevent and reduce prescription drug abuse
Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies
Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to drug pricing, generally
Issues related to the importation of prescription medicines
MMM - Medicare/Medicaid PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY VINCENT A. ROBERTI, SR.